Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects

Next Previous
Trial Profile

A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zetomipzomib (Primary) ; Zetomipzomib (Primary)
  • Indications Autoimmune haemolytic anaemia; Dermatomyositis; Lupus nephritis; Polymyositis; Systemic lupus erythematosus; Thrombocytopenia
  • Focus Adverse reactions
  • Sponsors Kezar Life Sciences

Most Recent Events

  • 01 Oct 2019 According to a Kezar Life Sciences media release, data from the study will be presented at the upcoming 2019 ACR/ARP Annual Meeting.
  • 06 Mar 2019 According to a Kezar Life Sciences media release, data from this trial may be used to support development and potential regulatory approval.
  • 06 Mar 2019 Status changed from not yet recruiting to recruiting, according to a Kezar Life Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top